基于温度转换封装策略构建内部NP/外部M2e仿生VLP流感疫苗
研究基于乙肝核心病毒样颗粒(HBc VLP)构建仿生双抗原流感疫苗,内部封装保守核蛋白(NP)抗原肽、外部展示基质蛋白2胞外域(M2e)抗原。小鼠腹腔免疫后,该疫苗诱导的NP和M2e特异性抗体强于单抗原疫苗;H1N1致死攻击后无佐剂条件下提供100%保护且无明显体重下降,而非仿生双抗原疫苗保护率仅62.5%并伴12.5%体重下降。
要点
- 仿生双抗原VLP疫苗诱导的NP和M2e特异性抗体强于单抗原疫苗。
- H1N1致死攻击后仿生疫苗无佐剂提供100%保护且无显著体重下降。
- 仿生疫苗组生发中心B细胞和效应记忆CD8+ T细胞反应更高效。
核心结论
- 仿生方式组装和展示抗原的VLP策略有望用于高效通用流感疫苗及快速出现的病原体疫苗开发。
研究设计与样本
- 基于HBc VLP,采用温度转换封装策略构建内部NP/外部M2e仿生双抗原疫苗,并构建非仿生双抗原疫苗及四种单抗原VLP疫苗作为对照。
- 小鼠腹腔免疫后评估抗体应答,并进行H1N1致死攻击保护实验。
主要发现
- 仿生双抗原VLP疫苗诱导的NP和M2e特异性抗体强于单抗原疫苗。
- H1N1致死攻击后,仿生双抗原疫苗无佐剂条件下提供100%保护且无明显体重下降。
- 非仿生双抗原疫苗保护率仅62.5%,免疫小鼠伴12.5%体重下降。
- 仿生疫苗组生发中心B细胞形成更高效,效应记忆CD8+ T细胞水平更高。
关键数值与推荐
- 仿生双抗原疫苗小鼠H1N1致死攻击后保护率为100%,非仿生双抗原疫苗为62.5%。
- 非仿生双抗原疫苗免疫小鼠体重下降12.5%。
临床怎么用
- 提示仿生抗原展示策略可增强VLP疫苗的体液和细胞免疫应答,为通用流感疫苗设计提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Here we present a biomimetic strategy towards an influenza vaccine design based on hepatitis B virus core virus-like particles (HBc VLP). To this end, a temperature-shift based encapsulation process based on analysis of the unique thermal-associated structural flexibility of HBc VLP nanocages was proposed and proved efficient for encapsulation of antigen inside the VLP. By displaying a matrix protein 2 ectodomain (M2e) antigen on the exterior of HBc VLP through genetic fusion, and encapsulate a conserved internal nucleoprotein (NP) antigen peptide inside the VLP, a biomimetic dual-antigen influenza vaccine with interior NP/exterior M2e was constructed. For comparison, another non-biomimetic dual-antigen vaccine with interior M2e/exterior NP, and other four VLP-based single-antigen vaccines with NP or M2e either being encapsulated inside or genetically displayed outside the VLP were also constructed. Upon intraperitoneal immunization in mice, the dual-antigen VLP influenza vaccine elicited both NP and M2e-specific antibodies, which were stronger than those elicited by the single-antigen vaccines. Most importantly, after a lethal challenge of H1N1 virus, the biomimetic dual-antigen vaccine conferred the mice 100% protection without noticeable body weight loss in the absence of any adjuvant. While the protective efficacy conferred by the non-biomimetic one was only 62.5%, accompanying 12.5% body weight loss in the immunized mice. Besides the high level of antigen-specific antibodies, more efficient formation of total germinal center (GC) B cells and a higher level of effector memory CD8+ T cell population were observed in the biomimetic vaccine group, as compared with the non-biomimetic one. All these results demonstrate that VLP assembly and display of antigens in a biomimetic manner making this a promising strategy for the production of efficient universal vaccines to influenza and other rapidly emerging pathogens.
引用
- Wei J, Li Z, Yang Y, et al. A biomimetic VLP influenza vaccine with interior NP/exterior M2e antigens constructed through a temperature shift-based encapsulation strategy. Vaccine. 2020. PMID: 32713681. doi:10.1016/j.vaccine.2020.07.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。